title: Iron chelator differentially activates macrophage inflammatory protein-3alpha/CCL20 in immortalized and malignant human oral keratinocytes.
abstract: Macrophage inflammatory protein-3alpha (MIP-3alpha or CCL20) is an intriguing molecule in cancer immunotherapy, but MIP-3alpha expression and signalling are not well understood in oral cancer cells. We investigated CCL20 expression and signal transduction by treating immortalized human oral keratinocyte (IHOK) and oral cancer (HN4) cells with deferoxamine (DFO) and examined the mRNA expression of CCL20 using RT-PCR and ELISA. IHOK and HN4 cells treated with DFO showed increased mRNA and protein expression of CCL20, and the upregulation of DFO-induced CCL20 expression was higher in IHOK cells than in HN4 cells. Selective inhibitors of p38 and ERK1/2 abolished DFO-induced CCL20 expression in both IHOK and HN12 cells, and p38 and ERK1/2 inhibitors prevented DFO-induced degradation of I-kappaB and NF-kappaB activation. Activation of c-fos and c-jun also occurred following DFO treatment in IHOK and HN4 cells. Collectively, these results suggest that DFO-induced MIP-3alpha, which is involved in the MAP kinase, c-fos, c-jun, and NF-kappaB pathways, may be an important mediator of the antitumour immune response in oral keratinocytes and warrants consideration as a target molecule for oral cancer treatment.
authors.affiliation: Department of Oral and Maxillofacial Pathology, Wonkwang University, Iksan, South Korea.
authors.forename: Sun-Kyung
authors.initials: SK
authors.lastname: Lee
authors.forename: Jun
authors.initials: J
authors.lastname: Lee
authors.forename: Seung-Ki
authors.initials: SK
authors.lastname: Min
authors.forename: Dal-Ho
authors.initials: DH
authors.lastname: Won
authors.forename: You-Mee
authors.initials: YM
authors.lastname: Lee
authors.forename: Hyun-Dae
authors.initials: HD
authors.lastname: Lim
authors.forename: Wan
authors.initials: W
authors.lastname: Lee
authors.forename: Hyun-Ock
authors.initials: HO
authors.lastname: Pae
authors.forename: Hun-Taeg
authors.initials: HT
authors.lastname: Chung
authors.forename: Chang-Duk
authors.initials: CD
authors.lastname: Jun
authors.forename: Suk-Keun
authors.initials: SK
authors.lastname: Lee
authors.forename: Eun-Cheol
authors.initials: EC
authors.lastname: Kim
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000378:metabolism*; D054418:Chemokine CCL20 / Q000378:metabolism*; D003676:Deferoxamine / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005290:Ferric Compounds / Q000494:pharmacology; D015870:Gene Expression; D006801:Humans; D007502:Iron Chelating Agents / Q000494:pharmacology*; D015603:Keratinocytes / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D009062:Mouth Neoplasms / Q000378:metabolism*; D016328:NF-kappa B / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D014407:Tumor Cells, Cultured
chemical_list: C108355:CCL20 protein, human; D054418:Chemokine CCL20; D005290:Ferric Compounds; D007502:Iron Chelating Agents; D016328:NF-kappa B; C025314:ferric citrate; D003676:Deferoxamine